Moderna now in the crosshairs of Sens. Warren, Welch over price tag for COVID vaccine
Fierce Pharma
JANUARY 25, 2023
Warren, Welch over price tag for COVID vaccine kdunleavy Wed, 01/25/2023 - 13:16 Moderna now in the crosshairs of Sens.
tag pricing 
Sporting a $3.5M price tag, CSL and uniQure's hemophilia B gene therapy crosses FDA finish line
Fierce Pharma
NOVEMBER 23, 2022
price tag, CSL and uniQure's hemophilia B gene therapy crosses FDA finish line. Sporting a $3.5M Wed, 11/23/2022 - 10:10.
FDA 
302
302 FDA 302
302 Join 8,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Biogen’s Alzheimer’s drug: What’s the price tag on hope?
World of DTC Marketing
JUNE 1, 2021
If the drug is approved you can bet that it’s going to carry a huge price tag. It could carry a price tag as high as $50,000-a-year per patient, according to drug analysts, adding billions of dollars to the nation’s health tab. . Will they follow the science or will they put a price tag on hope?
Side effects 187
187 
Orchard sets new gene therapy price tag at $4.25M—the steepest of any drug in the US
Fierce Pharma
MARCH 20, 2024
Kyowa Kirin and its subsidiary Orchard Therapeutics have broken new boundaries in pricing, too. After scoring an FDA nod Monday for the first gene therapy to treat the rare genetic disease metachromatic leukodystrophy (MLD) in the U.S.,
FDA 261
261 FDA 261
261 
Can gene therapies for haemophilia defend their high price tags?
Pharmaceutical Technology
NOVEMBER 9, 2022
Despite their potential multi-million-dollar sticker price, if haemophilia treatments by BioMarin and CSL Behring prove durable, they could help patients save money compared to current treatments, experts note. A previous October 2020 report concluded that longer-term safety and efficacy were needed to update health-benefit price benchmarks.
Safety 111
111 
Amylyx ALS drug draws criticism over $158,000 price tag
pharmaphorum
OCTOBER 3, 2022
Amylyx Pharmaceuticals’ Relyvrio – a new treatment for amyotrophic lateral sclerosis (ALS) approved by the FDA on Thursday, after review of the data from its phase 2 trial – was the next day set at a list price of $158,000 per year in the US, sparking outcry. ALS affects over 30,000 people in the US.
Insurance 52
52 
ICER updates cost-effectiveness threshold for bluebird, Vertex and CRISPR's dueling sickle cell gene therapies
Fierce Pharma
JULY 14, 2023
The potentially curative promise of gene therapies often carries a steep price tag. | The potentially curative promise of gene therapies often carries a steep price tag. But for a pair of personalized medicine prospects in sickle cell disease (SCD), the cost could be worth it, at least as far as ICER is concerned.
Prospecting 199
199 
Bluebird won't play off Vertex in deciding price for its lovo-cel gene therapy, exec says
Fierce Pharma
NOVEMBER 7, 2023
One potential advantage for bluebird, giving the timing, could be a chance to view its rival's pricing before deciding itself. But on Tuesday bluebird said that Vertex’s price tag will not factor into how the Massachusetts company will price its treatment.
FDA 214
214 FDA 214
214 
Pfizer’s First Gene Therapy Approval Sets Up a Showdown With CSL in Hemophilia B
MedCity News
APRIL 26, 2024
million price tag, the same as a CSL Behring gene therapy already available for treating the inherited bleeding disorder. The FDA has approved Beqvez, a Pfizer gene therapy developed for moderate-to-severe hemophilia B. The one-time treatment carries a $3.5
FDA 101
101 
Orchard’s MLD gene therapy becomes costliest US medicine
pharmaphorum
MARCH 20, 2024
Orchard Therapeutics has revealed the US price of Lenmeldy, its gene therapy for rare disease MLD, placing a $4.25m price tag on the one-shot treatment
Medicine 104
104 Medicine 104
104 
Turnover in Pharma: Revealing the Price Tag
Revosuite
JUNE 18, 2019
The post Turnover in Pharma: Revealing the Price Tag appeared first on REVO. But how does that influence a company’s bottom line? What are the consequences to that “memory loss”? According to Panopto’s.
Pharma 52
52 
Sanders takes aim at US drug prices of Novo’s Ozempic and Wegovy
Pharmaceutical Technology
APRIL 25, 2024
A Senate Committee is investigating the “outrageously high” US price tags of the blockbuster diabetes and obesity drugs.
52 
Beyond the Price Tag: How Hospital Admins, Doctors, and Patients Define Medical Value
Contrarian Sales Techniques
OCTOBER 19, 2023
It's not just about the price anymore. In this context, value might mean access to cutting-edge treatments, transparent pricing, or a supportive healthcare community that empowers them to make informed choices. In the ever-evolving world of healthcare, the term "value" has taken on a myriad of meanings.
Doctors 52
52 
Revolutionizing Rare Disease Treatment: Embracing the Patient-Centric Transformation in Pharmaceutical Customer Engagement
Pharmaceutical Commerce
MARCH 6, 2024
Navigating the complex landscape of healthcare coverage can be an intimidating task, especially for patients with rare diseases for which treatments often come with a high price tag.
Patients 59
59 
FDA approves Duchenne gene therapy with hefty $3.2m price tag
Pharmaceutical Technology
JUNE 23, 2023
Sarepta will now need to complete a confirmatory trial to prove the therapy improves physical function and mobility.
FDA 52
52 FDA 52
52 
Healthcare doesn’t give a damn about patients
World of DTC Marketing
JULY 20, 2022
have raised drug prices 1,186 times so far this year. Patients for Affordable Drugs found that between June 24 and July 5, pharmaceutical companies increased prices for 133 products. Pfizer, for instance, hiked the cost of its leukemia medication Besponsa again this month, bringing its per-vial price tag to $21,056.
Healthcare 183
183 
Pharma Pulse 3/29/24: Super Micro’s AI Boom Carries a Big Price Tag, Leveraging Digital Tools to Optimize Manufacturing & more
PharmExec
MARCH 29, 2024
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Novartis pays $100M to get Mallinckrodt’s ticket for a speedier FDA drug review
MedCity News
JULY 1, 2022
The $100 million price tag is in the neighborhood of the going rate for these vouchers, which grant a company a shorter regulatory review timeline for a drug that addresses a rare or neglected disease. Novartis is acquiring an FDA priority review voucher from Mallinckrodt Pharmaceuticals.
FDA 107
107 
Coherus plans Humira biosimilar sale at 85% discount
Pharmaceutical Technology
JULY 14, 2023
Yusimry is priced at $995 per carton of two autoinjectors compared to Humira’s price tag of $6,922 for the same quantity.
Sales 52
52 Sales 52
52 
bluebird bio wins back-to-back landmark FDA approvals for first-in-class gene therapies
Pharmaceutical Technology
SEPTEMBER 30, 2022
Spark Therapeutics’ Luxturna, indicated for inherited retinal disease (IRD), was the first gene therapy to be approved, in 2017, with a price tag of $850,000 for each eye. bluebird then broke its own pricing record when the $3m Skysona was approved, and now faces the unique challenge of selling the world's two most expensive drugs.
FDA 115
115 
Medicare savings won’t make a dent in healthcare costs
World of DTC Marketing
SEPTEMBER 9, 2021
SUMMARY: Allowing Medicare to negotiate drug prices is popular with voters because the media has been focused on the high price of some drugs, but this measure won’t lead to lower healthcare costs. Generally, healthcare prices are higher in the U.S. healthcare spending will reach $6.2 healthcare. healthcare spending.
Healthcare 222
222 
Widespread Implementation of Long-Acting PrEP for HIV May Be Stifled By High Price Tag, Say Researchers
Pharmacy Times
DECEMBER 12, 2022
Following the approval of cabotegravir in 2021, governments and donor agencies in low- and middle-income countries are contemplating replacing oral pre-exposure prophylaxis or augmenting the approach with long-acting treatment.
Government 49
49 Government 49
49 
The current pharma business model is unsustainable
World of DTC Marketing
SEPTEMBER 7, 2022
In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. The average American with cancer can do the math and come to the same conclusion that some oncology experts are coming to: Cancer drugs are priced too high.”
Pharma 210
210 
Critical Success Factors for Commercializing Specialty Drugs, Cell and Gene Therapies
Pharmacy Times
APRIL 17, 2023
Although payers have become somewhat accustomed to the high cost of specialty drugs, the price tags for gene therapies are causing “sticker shock.”
49 
US Government Purchases 66 Million Doses of Moderna’s COVID-19 Booster Candidate
Pharmaceutical Commerce
AUGUST 1, 2022
Price tag for bivalent dose was $1.74 billion.
Government 59
59 Government 59
59 
Cost of disease-modifying therapies for multiple sclerosis continues to rise in US
Pharmaceutical Technology
MAY 19, 2023
DMTs for MS have a high price tag, particularly in the US. A similar trend of price increases was also seen for MS generics and biosimilars. However, they cannot provide a cure and have a very limited impact on halting disease progression.
Prospecting 98
98 
Risk-sharing agreements are growing at a rate of 24%
Pharmaceutical Technology
FEBRUARY 10, 2023
On November 22, 2022, the FDA approved CSL Behring’s Hemgenix (etranacogene dezaparvovec), the first gene therapy treatment for hemophilia B, with a staggering manufacturer price of $3.5 million, according to GlobalData’s Price Intelligence (POLI), making it the most expensive drug in the world.
Marketing 105
105 
What is Biogen and can they repair their reputation?
World of DTC Marketing
SEPTEMBER 24, 2021
Then, against the advisory panel’s advice, Aduhelm was approved, but insiders within the industry criticized both the FDA and Biogen weren’t sold on the drug or its price tag. Many doctors also became upset at the idea of telling Alzheimer’s patients that the drug didn’t work.
Insurance 222
222 
Do healthcare mergers and acquisitions lead to better care for patients?
Clarify Health
NOVEMBER 22, 2023
But consolidation in healthcare markets is not with its critics, with some experts raising concerns over increasing prices due to decreased competition and eliminating services. With higher price tags, the incentive for quality improvement is lower, setting back efforts to drive value-based care.
Leads 52
52 
Free access to Zolgensma curbed, says Novartis
pharmaphorum
JANUARY 9, 2023
” Zolgensma is one of the most expensive therapies available, with a price tag of around $2.1 million in the US and just under €2 million in Europe, which the company says is justified by its dramatic benefits when given as a one-shot therapy to patients with SMA.
Side effects 113
113 
Axsome bounces back as FDA clears depression drug
pharmaphorum
AUGUST 21, 2022
There’s no word yet on its pricing, but for comparison Spravato was launched with an annual price tag of around $32,400, which the Institute for Clinical and Economic Review (ICER) concluded was around 25% to 52% too high to be cost effective.
FDA 87
87 
American health is in for a “world of hurt”
World of DTC Marketing
NOVEMBER 3, 2020
An #NHLBI-funded study put a price tag on American’s bad eating habits: $50 billion a year in health care costs, attributable to cardiometabolic diseases such as heart disease, stroke and type 2 diabetes.
Insurance 190
190 
Upcoming sickle cell gene therapies cost effective at $2 million, says ICER
Pharmaceutical Technology
APRIL 13, 2023
Two gene therapies up for approval this year for sickle cell disease could be cost effective in some cases at a $2 million price point, based on a draft evidence report published by the Institute for Clinical and Economic Review (ICER). Since the price of the therapies is unknown, the institute used a placeholder cost of $2 million.
Healthcare 59
59 
Global (68M) cardiomyopathies market projected to grow to $9.63bn by 2031
Pharmaceutical Technology
DECEMBER 15, 2022
The US is set to dominate the cardiomyopathy landscape because of the country’s high prevalence of dilated cardiomyopathy (DCM) relative to the other markets in the 7MM, as well as the higher price tag on US-marketed therapeutics. The second highest contributing market is APAC, generating 33.2%
Marketing 52
52 
The FDA and Aduhelm: WTF?
World of DTC Marketing
JUNE 23, 2021
Not to mention the $56,000 annual price tag. Aduhelm joins a group of drugs that potentially leave patients worse off and much poorer for it. Recall that with this drug, about 30–40 percent of study participants experienced either brain swelling or bleeding.
FDA 218
218 
Novel nanofiltration method for microbial biosurfactant downstream processing
European Pharmaceutical Review
JUNE 8, 2023
However, the price of the cheapest mBs is ten-fold in cost compared to chemical surfactants. Methods of the microbial biosurfactant study The first stage of the downstream method combined TAG selective removal from glycolipids. This indicates that scalable fermentations and downstream processes are sub-optimised.
bluebird unveils $2.8m price for gene therapy Zynteglo on FDA approval
pharmaphorum
AUGUST 18, 2022
The US approval comes three years after Zynteglo (betibeglogene autotemcel) was approved for the same indication in Europe, and subsequently withdrawn after bluebird concluded that it wasn’t possible to build a commercially viable business for the gene therapy as the pricing and reimbursement environment there was too “hostile.”
FDA 52
52 
You can’t afford to get cancer
World of DTC Marketing
DECEMBER 13, 2021
As cancer survival rates rise, so do the price tags of life-saving treatments. Even worse, others are completely priced out of the hope for a cure. 11 of the 12 cancer drugs that the Food and Drug Administration approved in 2012 were priced at more than $100,000 per year. billion included out-of-pocket costs of $16.22
ASH: Argenx cues up a second use for efgartigimod
pharmaphorum
DECEMBER 12, 2022
Vyvgart is already approved to treat generalised myasthenia gravis, getting a green light for that indication from the FDA a year ago, and launched with a $225,000 per annum price tag in competition with rival gMG drugs like AstraZeneca/Alexion’s C5 inhibitor Soliris (eculizumab).
Side effects 52
52 
Why Pricing Is The Backbone Of Your Sales Strategy & How To Do It Right
CloserIQ
APRIL 8, 2019
Most startups spend more time thinking about the color of their logo than how to price their product. This might sound harsh, but here’s the truth: The color of your logo will not save you if you price your product wrong. Pricing is one of the most important parts of a startup’s sales strategy, but it’s often overlooked.
Versanis’ bimagrumab, first-in-class obesity therapy, enters Phase IIb of development
Pharmaceutical Technology
JANUARY 17, 2023
Despite its high price tag, bimagrumab’s unique features set it apart from currently marketed therapies.
Marketing 52
52 
After a slow start for expensive CAR-T therapies, drug developers revisit oral therapies for blood cancer
pharmaphorum
DECEMBER 23, 2022
price tag of $475,000 when it was first launched in 2017 – and it becomes apparent that these may not be desirable treatment options for every patient and in every setting. Add to this the considerable cost of these medications – the first approved CAR-T, Novartis’ Kymriah (tisagenlecleucel), had a U.S.
Side effects 52
52 
Orphan drugs and where to launch them: The keys to Europe’s forgotten territories
Pharmaceutical Technology
JULY 14, 2022
Due to the high price tags associated with these speciality medicines, innovators have naturally favoured big markets with high GDP such as the US and EU-5 (Germany, France, Spain, Italy, and the UK). “The Go-to-market strategies. The choice of where to launch an orphan drug is an important and difficult decision.
Medicine 59
59 
Rare Disease Spotlight – tracing the rise of orphan drug designations over almost 40 years
Pharmaceutical Technology
JUNE 29, 2022
Additionally, pricing and access for rare disease therapies continue to be scrutinized closely. For example, while orphan drug designations have more than doubled in the last decade compared to the previous one, only 16% of therapies with orphan tags have managed to gain FDA approval in some indications.
Let's personalize your content